LRMR Larimar Therapeutics Inc

Price (delayed)

$3.275

Market cap

$340.22M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.1

Enterprise value

$165.48M

Relative Growth: Rel. Growth:
Relative Strength: Rel. Strength:
Relative Valuation: Rel. Valuation:
Relative Profitability: Rel. Profitability: 1

Larimar Therapeutics, Inc., is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases. The company's lead compound, CTI-1601, is currently being evaluated in a Phase 1 clinical ...

Highlights
LRMR's equity has surged by 102% since the previous quarter and by 10% year-on-year
The debt has contracted by 22% YoY and by 7% from the previous quarter
LRMR's quick ratio has surged by 99% since the previous quarter but it is down by 41% year-on-year
The EPS has decreased by 40% YoY but it has increased by 7% from the previous quarter
The company's net income has shrunk by 74% YoY

Key stats

What are the main financial stats of LRMR

LRMR stock price

How has the Larimar Therapeutics stock price performed over time
Intraday
2.34%
1 week
-6.16%
1 month
-22.39%
1 year
33.67%
YTD
-14.04%
QTD
-27.22%

Financial performance

How have Larimar Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$172.43M
Net income
-$166.01M
Gross margin
N/A
Net margin
N/A
The company's net income has shrunk by 74% YoY
Larimar Therapeutics's operating income has shrunk by 64% YoY

Price vs fundamentals

How does LRMR's price correlate with its fundamentals

Growth

What is Larimar Therapeutics's growth rate over time

Valuation

What is Larimar Therapeutics stock price valuation
P/E
N/A
P/B
2.15
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has decreased by 40% YoY but it has increased by 7% from the previous quarter
LRMR's equity has surged by 102% since the previous quarter and by 10% year-on-year
LRMR's P/B is 22% below its last 4 quarters average of 2.7 but 5% above its 5-year quarterly average of 2.0

Efficiency

How efficient is Larimar Therapeutics business performance
LRMR's ROE has dropped by 155% year-on-year but it is up by 2.6% since the previous quarter
Larimar Therapeutics's ROA has plunged by 108% YoY but it has increased by 5% from the previous quarter
The ROIC has plunged by 99% from the previous quarter

Dividends

What is LRMR's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for LRMR.

Financial health

How did Larimar Therapeutics financials performed over time
LRMR's quick ratio has surged by 99% since the previous quarter but it is down by 41% year-on-year
The current ratio has surged by 96% since the previous quarter but it has declined by 43% year-on-year
The debt is 98% less than the equity
LRMR's equity has surged by 102% since the previous quarter and by 10% year-on-year
LRMR's debt to equity has plunged by 60% from the previous quarter and by 33% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.